Uploaded November 2026 | Updated November 2026, 12 hours ago
A post-hoc analysis of the phase 3 TETON-2 study, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that inhaled treprostinil significantly reduced multiple disease progression events in patients with idiopathic pulmonary fibrosis (IPF).
Steven Nathan, MD, MBBCh, FCCP, Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital, discusses the findings and their implications for patients.
A post-hoc analysis of the phase 3 TETON-2 study, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that inhaled treprostinil significantly reduced multiple disease progression events in patients with idiopathic pulmonary fibrosis (IPF).
Steven Nathan, MD, MBBCh, FCCP, Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital, discusses the findings and their implications for patients.










